C2N Diagnostics Announces Collaborative Research and Global Exclusive Supplier Agreement With Cambridge Isotope Laboratories, Inc
7/15/2013 10:47:28 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
ST. LOUIS--(BUSINESS WIRE)--C2N Diagnostics (C2N) today announced that it has signed a collaborative research and a global, exclusive supplier agreement with Cambridge Isotope Laboratories, Inc (CIL). The partnership guarantees C2N’s future access to mass quantities of highly enriched stable isotopes at predictable prices. These stable isotopes are key reagents to C2N’s platform of Stable Isotope Labeling Kinetic (SILK™)-based biomarkers. Such biomarkers are showing considerable promise to detect early Alzheimer’s pathology (i.e., well before the onset of clinical symptoms) as well as to measure treatment responsiveness in preclinical and clinical drug studies.
Help employers find you! Check out all the jobs and post your resume.
comments powered by